Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs
- PMID: 7786396
Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs
Abstract
Combretastatin A-4 (1a), the principal cancer cell growth-inhibitory constituent of the Zulu medicinal plant Combretum caffrum, has been undergoing preclinical development. However, the very limited water solubility of this phenol has complicated drug formation. Hence, derivatives of the combretastatin A-4 (1a) 3'-phenol group were prepared for evaluation as possible water-soluble prodrugs. As observed for combretastatin A-4, the sodium salt (1b), potassium salt (1c) and hemisuccinic acid ester (1e) derivatives of phenol 1a were essentially insoluble in water. Indeed, these substances regenerated combretastatin A-4 upon reaction with water. A series of other simple derivatives (1d, 1f-j) proved unsatisfactory in terms of water solubility or stability, or both. The most soluble derivatives evaluated included the ammonium (1l), potassium (1m) and sodium (1n) phosphate salts, where the latter two proved most stable and suitable. Both the potassium (1m) and sodium (1n) phosphate derivatives of combretastatin A-4 were also found to exhibit the requisite biological properties necessary for a useful prodrug. Sodium salt 1n was selected for drug formulation and further pre-clinical development.
Similar articles
-
Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs.Anticancer Drug Des. 2000 Jun;15(3):203-16. Anticancer Drug Des. 2000. PMID: 11049088
-
Antineoplastic agents 393. Synthesis of the trans-isomer of combretastatin A-4 prodrug.Anticancer Drug Des. 1998 Dec;13(8):981-93. Anticancer Drug Des. 1998. PMID: 10335271
-
Antineoplastic agents. 379. Synthesis of phenstatin phosphate.J Med Chem. 1998 May 7;41(10):1688-95. doi: 10.1021/jm970644q. J Med Chem. 1998. PMID: 9572894
-
Medicinal chemistry of combretastatin A4: present and future directions.J Med Chem. 2006 Jun 1;49(11):3033-44. doi: 10.1021/jm0512903. J Med Chem. 2006. PMID: 16722619 Review. No abstract available.
-
Combretastatin A-4 analogues as antimitotic antitumor agents.Curr Med Chem. 2003 Sep;10(17):1697-722. doi: 10.2174/0929867033457151. Curr Med Chem. 2003. PMID: 12871118 Review.
Cited by
-
Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4',5-trimethoxylstilbene-3'-O-phosphate disodium (M410).Invest New Drugs. 2011 Apr;29(2):300-11. doi: 10.1007/s10637-009-9366-x. Epub 2009 Dec 11. Invest New Drugs. 2011. PMID: 20012336
-
Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.Br J Cancer. 2003 Aug 4;89(3):437-54. doi: 10.1038/sj.bjc.6601106. Br J Cancer. 2003. PMID: 12888809 Free PMC article. No abstract available.
-
Design, synthesis, docking study and anticancer evaluation of new trimethoxyphenyl pyridine derivatives as tubulin inhibitors and apoptosis inducers.RSC Adv. 2021 Dec 13;11(63):39728-39741. doi: 10.1039/d1ra07922k. eCollection 2021 Dec 13. RSC Adv. 2021. PMID: 35494162 Free PMC article.
-
Regioselective synthesis of water-soluble monophosphate derivatives of combretastatin A-1.J Nat Prod. 2011 Jul 22;74(7):1568-74. doi: 10.1021/np200104t. Epub 2011 Jun 30. J Nat Prod. 2011. PMID: 21718055 Free PMC article.
-
Synthesis and antineoplastic properties of (1H-1,2,3-triazol-1-yl)furazans.Russ Chem Bull. 2013;62(3):836-843. doi: 10.1007/s11172-013-0113-2. Epub 2014 Jan 7. Russ Chem Bull. 2013. PMID: 32214776 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials